0AAJ.LSE PolyPeptide Group AG
- Market cap
- -
- P/E
- 29.1x
- P/B
- -
- ROE
- 10.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0AAJ.LSE undervalued?
Graham numberThe Graham number of PolyPeptide Group AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PolyPeptide Group AG fundamental analysis
No fundamental analysis for PolyPeptide Group AG yet.
PolyPeptide Group AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as wel…
Full company profilePolyPeptide Group AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PolyPeptide Group AG annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 181M | 203M | 224M | 282M | 281M | 320M | 337M | 392M | 945M |
| Gross Profit | 64.0M | 59.1M | 73.2M | 99.7M | 52.0M | 4.77M | 37.5M | 64.3M | 213M |
| Operating Income | 28.1M | 33.5M | 44.3M | 64.2M | 12.6M | -36.5M | -7.36M | 7.41M | 46.8M |
| EBITDA | 40.8M | 49.3M | 62.0M | 87.8M | 38.6M | -6.27M | 24.7M | 44.4M | 155M |
| Net Income | 23.8M | 25.7M | 31.3M | 47.3M | 7.77M | -51.4M | -19.6M | -21.3M | 36.3M |
| EPS | 0.79 | 0.86 | 1.04 | 1.47 | 0.24 | -1.56 | -0.59 | -0.65 | 1.10 |
| Balance Sheet | |||||||||
| Total Assets | 284M | 305M | 376M | 595M | 576M | 689M | 757M | 825M | 863M |
| Total Liabilities | 136M | 156M | 198M | 174M | 154M | 308M | 399M | 485M | 511M |
| Shareholders' Equity | 148M | 149M | 178M | 421M | 422M | 381M | 357M | 340M | 352M |
| Cash & Short-term Investments | 10.0M | 17.5M | 17.2M | 136M | 37.5M | 95.7M | 68.3M | 74.5M | 59.2M |
| Total Debt | 43.3M | 47.3M | 51.8M | 29.5M | 31.7M | 125M | 105M | 130M | 140M |
| Cash Flow | |||||||||
| Operating Cash Flow | 22.9M | 55.6M | 49.5M | 57.4M | 5.41M | 36.5M | 89.4M | 78.0M | 101M |
| Capital Expenditure | 14.5M | 17.5M | 40.6M | 74.0M | 74.4M | 52.9M | 85.8M | 108M | 175M |
| Free Cash Flow | 8.42M | 38.1M | 8.86M | -16.6M | -68.9M | -16.4M | 3.65M | -30.4M | -73.9M |
| Ratios | |||||||||
| ROE | 16.1% | 17.2% | 17.6% | 11.2% | 1.8% | -13.5% | -5.5% | -6.3% | 10.3% |
| ROA | 8.4% | 8.4% | 8.3% | 7.9% | 1.3% | -7.5% | -2.6% | -2.6% | 4.2% |
| Net Profit Margin | 13.2% | 12.7% | 14.0% | 16.8% | 2.8% | -16.1% | -5.8% | -5.4% | 3.8% |
| Debt to Equity | 0.29x | 0.32x | 0.29x | 0.07x | 0.08x | 0.33x | 0.29x | 0.38x | 0.40x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PolyPeptide Group AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | GBP 9.57M | 0.29 | 123.3% |
| 2021 | GBP 9.67M | 0.30 | 20.5% |
| 2020 | GBP 9.67M | 0.32 | 30.9% |
| 2019 | GBP 9.67M | 0.32 | 37.6% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PolyPeptide Group AG
- Insiders 57.20%
- Institutions 11.99%
- Public & others 30.81%
- Free float 14.1M
PolyPeptide Group AG company profile
- Company name
- PolyPeptide Group AG
- Ticker
- 0AAJ.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,460
- Fiscal year end
- December
- Address
- Neuhofstrasse 24, Baar, Switzerland, 6340
- Phone
- 41 435 020 580
- Website
- polypeptide.com
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
PolyPeptide Group AG management
10- Mr. Juan Jose GonzalezChief Executive Officer · born 1972
- Mr. Tim BrandlInterim CFO and Director of Investor Relations, Financial Planning & Analysis
- Rene VestergaardDirector of Corporate Finance
- Mr. Olivier Ludemann-HombourgerDirector of Global Innovation & Technology · born 1972
- Ms. Christina Del VecchioChief Legal Officer & Corporate Secretary · born 1978
- Andreas LieseCorporate Compliance Manager
- Lauren StarrHead of Communications
- Ms. Monika CasanovaChief Human Resources Officer · born 1979
- Christophe ChevalierHead of Capex & Strategic Projects
- Krister SvardChief Information Security Officer & Global IT Services VC